Addex Therapeutics (ADXN) Cash from Operations (2019 - 2026)
Addex Therapeutics (ADXN) posted Cash from Operations of 977983819680.77 for Q1 2026, down 235.24% sequentially from 723169897008.2 in Q2 2025, and down 46.86% YoY from 1840530593754.88 in Q1 2025.
Addex Therapeutics (ADXN) Cash from Operations (2019 - 2026) Analysis & Trends
Addex Therapeutics has reported Cash from Operations for 8 years, with the latest figure at 977983819680.77 in Q1 2026.
- Quarterly Cash from Operations fell 46.86% year-over-year to 977983819680.77 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5186408478075.25 (up 206.39% YoY) and the FY2025 annual result came in at 2618646.08, up 57.13% from the prior year.
- Cash from Operations declined to 977983819680.77 in Q1 2026 per ADXN's latest filing, from 723169897008.2 in the prior quarter.
- Over five years, Cash from Operations peaked at 8307903520167.39 in Q4 2023 and troughed at 6175000729211.9 in Q3 2024.
- A 5-year average of 67285769162.26 and a median of 5245799.45 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations surged 260549967.07% in 2023, then sank 98554399.5% in 2024.
- Over 5 years, Cash from Operations stood at 3188604.01 in 2022, then soared by 260549967.07% to 8307903520167.39 in 2023, then fell by 26.49% to 6107133470013.81 in 2024, then tumbled by 88.16% to 723169897008.2 in 2025, then slumped by 235.24% to 977983819680.77 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 977983819680.77, 723169897008.2, and 665911069265.99 for Q1 2026, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - | -977.98 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -977.98 Bn |
| Mar 31, 2026 | -977.98 Bn |
| Jun 30, 2025 | 723.17 Bn |
| Jun 30, 2025 | 723.17 Bn |
| Mar 31, 2025 | -665.91 Bn |
| Mar 31, 2025 | -665.91 Bn |
| Dec 31, 2024 | 6,107.13 Bn |
| Dec 31, 2024 | 6,107.13 Bn |
| Sep 30, 2024 | -6,175.00 Bn |
| Sep 30, 2024 | -6,175.00 Bn |
| Jun 30, 2024 | 2,426.52 Bn |
| Jun 30, 2024 | 2,426.52 Bn |
| Mar 31, 2024 | -2,514.06 Bn |
| Mar 31, 2024 | -2,514.06 Bn |
| Dec 31, 2023 | 8,307.90 Bn |
| Dec 31, 2023 | 8,307.90 Bn |
| Sep 30, 2023 | -2,549.75 Bn |
| Sep 30, 2023 | -2,549.75 Bn |
| Jun 30, 2023 | -5,691.29 Bn |
| Jun 30, 2023 | -5,691.29 Bn |